Open any pharma technology vendor's website today and you will find the phrase “AI-powered” within the first two sentences. It is on the landing pages of CRM platforms, KOL databases, insights management tools, and compliance systems. It appears in pitch decks from startups founded last year and incumbents founded two decades ago. The phrase has become the minimum viable marketing claim in healthcare technology — so universal that it communicates almost nothing about what a product actually does.
This is a problem for Medical Affairs leaders. Not because AI is irrelevant — it is genuinely transformative for certain MSL workflows — but because the signal-to-noise ratio has collapsed. When every tool claims AI capabilities, the burden shifts entirely to the buyer to distinguish between products that have built real intelligence into their architecture and products that have wrapped an API call to GPT-4 in a chatbot interface and called it innovation.
This piece is an attempt to reset that conversation. Not to argue that AI is overhyped or underhyped, but to be specific about where it creates genuine value for MSL teams, where it falls short today, and how Medical Affairs leaders can evaluate AI claims without a computer science degree.
The AI Hype Cycle in Pharma
The timeline is instructive. In late 2022, OpenAI released ChatGPT and triggered the fastest technology adoption curve in history. Within months, every enterprise software company in every industry had an AI strategy — or at least an AI slide in their investor deck. Pharma was no exception. By mid-2023, the conference circuit was saturated with panels on “AI in Medical Affairs,” “AI-Driven KOL Engagement,” and “The Future of AI in Pharma.” By 2024, the vendor landscape had split into three categories.
The first category was genuinely new products built around AI capabilities from the ground up — platforms designed to solve specific pharmaceutical problems using modern machine learning and natural language processing. These were relatively rare.
The second category was existing products that had integrated meaningful AI capabilities into their workflows. A KOL database that added AI-driven entity resolution. A CRM that built intelligent call planning. A literature monitoring tool that added automated summarization. These integrations varied widely in quality, but the effort was real.
The third category — and by far the largest — was existing products that added a chatbot interface, rewrote their marketing copy to include “AI-powered,” and changed nothing else of substance. A text field that sends your question to a language model and returns an answer is not AI-powered KOL intelligence. It is a chatbot sitting on top of a database. The distinction matters because the problems MSLs face are not “I need to ask a question and get an answer” — they are “I need a system that continuously surfaces the right information at the right time without me having to ask.”
The pharma-specific challenge compounds this. Healthcare data is not like e-commerce data or financial data. It is fragmented across dozens of public and proprietary sources. It is unstructured — publication abstracts, clinical trial narratives, conference presentations. It is regulated, with strict boundaries around how information can be used and communicated. It requires domain expertise to interpret. A general-purpose language model that can write a convincing essay about oncology is not the same as a system that can accurately parse a PubMed abstract, resolve the author to a specific healthcare professional, score that publication's relevance to a therapeutic area, and update a KOL profile accordingly.
The non-promotional mandate adds another layer. MSLs operate under strict compliance constraints — everything they communicate must be scientifically balanced, non-promotional, and medically accurate. A generic AI that generates fluent but imprecise medical text is not just unhelpful in this context; it is a compliance liability. The bar for AI in Medical Affairs is not “can it generate text?” It is “can it generate accurate, balanced, compliant text grounded in verifiable sources?”
Which brings us to the only question that matters: where does AI actually create value for MSLs, and where is it theater?
Where AI Actually Works for MSLs
The honest answer is that AI excels at a specific category of MSL work: the labor-intensive data aggregation, pattern detection, and preparation tasks that consume a disproportionate share of MSL time without requiring the scientific judgment and relationship skills that define the role. These are not trivial tasks — they are essential — but they are tasks where computation genuinely outperforms human effort.
KOL Discovery and Profiling
This is where AI delivers the clearest, most defensible value. Identifying relevant KOLs for a specific therapeutic area requires cross-referencing publications in PubMed, clinical trial registrations on ClinicalTrials.gov, NIH grant awards, Open Payments data, conference abstracts, and institutional affiliations. Doing this manually for a single disease area can take weeks. Doing it comprehensively — including emerging voices, community-level treaters, and cross-disciplinary researchers — is effectively impossible without computational assistance.
AI adds specific value at multiple steps. Entity resolution — determining that “Dr. Sarah Chen” on a PubMed paper, “S. Chen, MD, PhD” on a clinical trial, and NPI 1234567890 are the same person — is a problem where machine learning dramatically outperforms manual matching. Relevance scoring — quantifying how central a particular HCP is to a specific disease area based on their publication history, trial involvement, and grant activity — requires processing volumes of data that no human team can replicate. Network analysis — mapping co-authorship relationships, institutional connections, and collaborative trial participation — reveals influence structures that are invisible to manual review.
The critical nuance: the scoring must be explainable. An MSL cannot walk into a meeting with a KOL and say “our AI identified you as important.” They need to know that Dr. Chen was surfaced because she published four papers on a specific mechanism of action in the past 18 months, serves as PI on a relevant Phase III trial, and was recently awarded an NIH R01 in the therapeutic area. Explainability is not a nice-to-have in MSL workflows — it is a functional requirement. Black-box AI that surfaces names without transparent reasoning will not be trusted, used, or useful. For a deeper framework on building a comprehensive KOL identification strategy, see our guide on identifying and prioritizing KOLs.
Literature Monitoring
MSLs are expected to maintain current knowledge of their therapeutic landscape. In practice, this means monitoring a constant stream of new publications, preprint postings, conference abstracts, and guideline updates. For a single disease area, PubMed alone may index hundreds of new papers per month. For a team covering multiple therapeutic areas, the volume is overwhelming.
AI handles this well. Natural language processing can scan incoming publications, assess their relevance to a specific therapeutic focus, extract key findings, and generate concise summaries. This is not replacing scientific analysis — it is triaging. Instead of an MSL scanning 200 abstracts to find the 15 that matter, the system surfaces those 15 with context on why they are relevant. The MSL still reads the papers, still forms their own scientific assessment, still determines what it means for their engagements. But the hours spent on initial screening are eliminated.
Pre-Call Intelligence
Before every significant KOL interaction, an MSL needs to prepare. What has this researcher published recently? Are they involved in any active clinical trials? Have they received industry payments, and from which companies? What did we discuss last time? Are there any new developments in their specific area of focus?
Assembling this information manually means logging into multiple systems, searching multiple databases, and synthesizing the results into a mental model of the KOL's current situation. Industry surveys consistently put pre-call preparation at 45-90 minutes per significant interaction. AI can reduce this to minutes by automatically aggregating every relevant data point — recent publications, trial updates, payment disclosures, previous interaction notes — into a structured briefing document. The MSL arrives prepared not just with facts, but with context: what has changed since the last meeting, what topics are likely to be of interest, and what questions the KOL might raise based on their recent work.
Insights Synthesis
MSLs capture insights from every meaningful interaction — observations about treatment practices, clinical concerns, competitive intelligence, unmet needs. Individually, these insights are anecdotal. Collectively, they represent one of the most valuable intelligence assets in pharmaceutical organizations. The problem, as we have written about in our analysis of the MSL technology landscape, is that insights are captured but almost never synthesized.
AI is uniquely suited to this task. Natural language processing can analyze hundreds of free-text insight entries, identify recurring themes, detect emerging trends, and quantify signal strength across regions and time periods. When eight MSLs across four territories independently note concerns about the same treatment protocol, that is a strategic signal. When sentiment around a competitor product shifts over a three-month period, that is market intelligence. These patterns are invisible in a CRM text field. They become visible when AI processes the corpus systematically.
Outreach Personalization
The initial outreach to a KOL is one of the most important — and most time-consuming — elements of MSL engagement. A generic email gets ignored. A scientifically relevant, personalized communication that references the KOL's actual research interests and recent work gets a response.
AI can draft these communications by analyzing a KOL's publication history, current research focus, and known therapeutic interests, then generating an outreach message that is specific, relevant, and scientifically grounded. The MSL still reviews, edits, and personalizes the draft — AI is not writing final copy. But it eliminates the blank page problem and reduces preparation time from 30 minutes per outreach to 5 minutes of review and refinement. Across a territory of 100+ KOLs, this is the difference between personalized engagement and templated mass communication.
Where AI Falls Short (Today)
Honesty about limitations is more valuable than enthusiasm about capabilities. The following are areas where AI either cannot help, should not be trusted, or is not yet reliable enough for Medical Affairs use cases.
Scientific Exchange Itself
The core of the MSL role is peer-to-peer scientific dialogue. This is an irreducibly human activity. An MSL sitting across from a leading oncologist, discussing the implications of a new biomarker study, navigating questions about clinical data, reading the room for unspoken concerns — this is not a workflow that AI automates. It requires scientific expertise, emotional intelligence, contextual judgment, and the kind of credibility that only comes from sustained professional relationships.
Any vendor that implies AI can participate in or replace scientific exchange is either confused about what MSLs do or counting on the buyer being confused. AI prepares the MSL for the conversation. The conversation itself is human.
Compliance Judgment
The line between medical education and product promotion is not a bright line — it is a context-dependent, judgment-intensive determination that varies by situation, audience, and regulatory environment. AI can flag potential compliance issues: a draft communication that uses promotional language, an interaction plan that might cross non-promotional boundaries, a suggested talking point that lacks sufficient clinical evidence. These checks are valuable as a safety net.
But the final compliance determination requires human expertise. The same statement can be appropriate in one context and problematic in another. A conversation that is perfectly compliant in a reactive medical information setting might be promotional in a proactive engagement. AI cannot reliably make these distinctions because they depend on contextual factors — the KOL's question, the setting, the prior conversation history, the regulatory landscape in that specific market — that current AI systems cannot fully model.
Strategic Relationship Building
AI can tell you who to meet. It can tell you when to meet them. It can even suggest what to discuss. What it cannot do is build trust. The MSL-KOL relationship is built over months and years through consistency, credibility, and authentic scientific engagement. It depends on follow-through: did the MSL actually deliver the clinical paper they promised? Did they connect the KOL with the right colleague? Did they remember a personal detail from the last conversation?
AI can support these behaviors — surfacing reminders, tracking commitments, maintaining context across interactions. But the relationship itself is a human artifact. The MSLs who build the strongest KOL networks do so because of who they are as scientists and professionals, not because of the tools they use. The best AI makes them more efficient at the logistics around relationship building. It does not and cannot replace the relationship.
Novel Scientific Interpretation
AI can summarize a paper. It can extract key findings, identify methodology, and compare results to prior studies. What it cannot do reliably is generate the kind of original scientific analysis that makes an MSL valuable in peer-to-peer dialogue. The ability to contextualize a new finding within the broader treatment landscape, to identify methodological nuances that affect interpretation, to connect results from disparate studies into a coherent clinical narrative — this requires deep domain expertise that current AI systems approximate but do not possess.
MSLs who rely on AI-generated scientific analysis without applying their own expertise will eventually be caught. KOLs are world-class scientists. They can tell the difference between an MSL who understands the data and one who is reciting a summary. AI-generated summaries are a starting point, not a substitute for scientific depth.
The Hallucination Problem
In most industries, an AI that occasionally generates plausible but incorrect information is inconvenient. In Medical Affairs, it is dangerous. A hallucinated clinical trial result, a fabricated publication reference, an incorrect adverse event statistic — any of these could have real consequences for patient safety and regulatory compliance. The hallucination problem is not solved. It is being managed — through retrieval-augmented generation, source attribution, human verification layers, and constrained output generation — but it is not solved.
This means that any AI tool deployed in Medical Affairs must have robust verification architecture. Every AI-generated claim should be traceable to a source. Every recommendation should be auditable. And every output that will be communicated externally must pass through human review. Tools that present AI output as authoritative without verification layers are not ready for Medical Affairs, regardless of how impressive their demos look.
The Copilot Framework
The right mental model for AI in Medical Affairs is the copilot, not the pilot. This is not a philosophical distinction — it is an architectural one that determines how AI should be integrated into MSL workflows and what outcomes you should expect.
Consider how an MSL's time is currently distributed. Industry data and internal analyses consistently show that 30-40% of MSL time is spent on activities that are essential but do not require their scientific expertise: searching databases, aggregating information, preparing briefing materials, documenting interactions, updating CRM records, monitoring literature, and assembling reports. This is the copilot zone — the work where AI can operate with high reliability and immediate impact.
The remaining 60-70% is the pilot zone: scientific dialogue with KOLs, strategic relationship building, compliance navigation, cross-functional collaboration, and the kind of nuanced judgment calls that define the MSL's value. AI assists here — surfacing context, suggesting approaches, flagging considerations — but the MSL is in command.
This framework has a practical implication that is often overlooked. The goal of AI for MSLs is not to automate the MSL role. It is to reclaim the 30-40% of time currently lost to manual data work and redirect it toward the high-value scientific engagement that MSLs were hired to do. A team of 50 MSLs recovering 15 hours per week each is the equivalent of adding 20 MSLs to the team — without hiring, training, or onboarding a single person.
The capacity implications extend further. With AI handling research, preparation, and documentation, each MSL can meaningfully engage with a significantly larger territory. Instead of deeply covering 30-40 KOLs and superficially covering another 50, an AI-augmented MSL can maintain substantive engagement across 80-100+ HCPs. This is not about doing more with less — it is about doing more with the same, by eliminating the manual work that constrains capacity.
Understanding how the complete MSL workflow operates end-to-end makes the copilot model concrete. At every stage — from KOL identification through engagement planning, pre-call preparation, interaction execution, insight capture, and strategic reporting — there are specific tasks where AI acts as copilot and specific tasks where the MSL is the pilot. The organizations getting this right are the ones that have mapped their workflow at this level of granularity, not the ones that deployed AI broadly and hoped it would find its own use cases.
The best AI tools are invisible. They do not ask the MSL to “use AI.” They surface the right information at the right time, in the right context, as a natural part of the workflow. If an MSL has to leave their primary workflow to interact with an AI feature, the integration has failed.
How to Evaluate AI Claims
If you are a Medical Affairs leader evaluating technology — or re-evaluating your current stack in light of AI developments — the following framework will help separate substance from marketing.
“What specific workflow step does this automate?”
This is the single most revealing question you can ask. A tool with genuine AI capabilities can point to a specific, named workflow step and explain how AI transforms it. “Our AI cross-references PubMed, ClinicalTrials.gov, and Open Payments data to continuously score KOL relevance for your therapeutic area, updating profiles within 48 hours of new data.” That is a specific claim about a specific workflow step with a specific mechanism.
Compare that with “Our AI-powered platform helps MSLs work smarter.” If the answer to “what does your AI do?” is vague, it is because the AI is vague. Push for specifics. If the vendor cannot name the exact workflow step, the exact data input, and the exact output, the AI is decorative.
“Where does the training data come from?”
This question separates domain-specific AI from generic AI. A tool that has built its own data pipelines — ingesting and structuring data from PubMed, NPI registries, clinical trial databases, payment disclosures, and conference proceedings — has a fundamentally different foundation than a tool that sends your question to a general-purpose language model. Both use AI. The results are not comparable.
Domain-specific data pipelines take years to build. They require entity resolution, data normalization, continuous updating, and deep understanding of healthcare data structures. This is the hard, unglamorous work that makes AI outputs accurate and reliable in Medical Affairs. A vendor that has done this work can explain their data architecture in detail. A vendor that has not will redirect the conversation to the chatbot interface.
“How does it handle compliance?”
In Medical Affairs, compliance is not a feature — it is a prerequisite. AI-generated content that will be shared with HCPs must be non-promotional, scientifically accurate, and grounded in approved data. Ask how the tool ensures this. Are there built-in compliance checks? Can outputs be audited against source data? Is there a human-in-the-loop review step before any AI-generated content reaches an external audience?
If the answer is “we'll figure that out later” or “that's the customer's responsibility,” walk away. A tool that generates fluent medical text without compliance architecture is a liability, not an asset.
“Can an MSL explain why the AI made this recommendation?”
Explainability is a practical requirement, not a theoretical one. When an AI surfaces a KOL as high-priority, the MSL needs to understand why — which publications, which trials, which data points drove the recommendation. When an AI suggests a discussion topic, the MSL needs to see the evidence supporting that suggestion. Without explainability, the tool will not be trusted. Without trust, it will not be adopted. Without adoption, the investment is wasted.
“What happens when the AI is wrong?”
Every AI system produces errors. The question is not whether errors occur but how the system handles them. Are there verification layers? Can the MSL trace any AI output back to its source data? Is there a feedback mechanism to improve accuracy over time? Does the system flag confidence levels so users can calibrate their trust?
A vendor that acknowledges error rates and describes their mitigation strategy is more trustworthy than one that claims 99% accuracy without evidence. In Medical Affairs, the cost of a false positive (engaging the wrong KOL) is wasted time. The cost of a false claim (communicating inaccurate medical information) is career-ending. The error architecture matters as much as the accuracy architecture.
Red Flags
- “AI-powered” with no specifics. If the vendor cannot explain what the AI actually does in technical terms, it is marketing copy, not a product capability.
- Demo-only features. Ask to see the AI features in a production environment with real data, not a curated demo. Features that work beautifully in a demo and fail at scale are more common than you think.
- Chatbot-as-product. A chatbot interface on top of your existing data is not a new product. It is a feature — and often a feature that creates more noise than signal because the underlying data was not structured for AI consumption.
- No source attribution. If AI outputs cannot be traced to specific data sources, the tool is generating information rather than processing it. In Medical Affairs, generated information is unreliable information.
- Promises of full automation. Any vendor claiming AI can fully automate MSL workflows either does not understand the MSL role or is deliberately overpromising. The MSL function is fundamentally about human scientific expertise and relationships. Tools that promise to replace that are selling a fiction.
The Trajectory
The question is no longer whether AI will transform MSL workflows — it is how quickly and in what sequence. The trajectory is becoming clear, and it favors organizations that adopt deliberately rather than those that wait for the technology to mature further.
Short-Term: 2026-2027
The immediate impact is in research, profiling, and preparation workflows. AI automates the data aggregation and synthesis tasks that currently consume a third of MSL time. KOL profiling becomes continuous rather than periodic. Pre-call preparation shrinks from an hour to minutes. Literature monitoring shifts from manual scanning to intelligent triage. The measurable outcome: MSLs gain back 10-15 hours per week, which translates directly to increased engagement capacity and deeper KOL relationships.
This is not speculative. The technology is production-ready today. The teams that are deploying it now are already seeing capacity gains that their competitors will spend the next two years trying to match.
Medium-Term: 2027-2029
As AI systems accumulate more data and interaction history, the capabilities evolve. Territory optimization becomes predictive — AI identifies which KOLs are likely to become influential in a therapeutic area before they reach peak visibility. Engagement timing becomes intelligent — the system identifies optimal moments for outreach based on publication activity, trial milestones, and historical response patterns. Insights synthesis becomes real-time — strategic signals surface as they emerge from field interactions rather than in quarterly reviews.
The organizational impact at this stage is structural. MSL teams cover dramatically more ground — not by working harder, but because the AI layer continuously optimizes territory allocation, engagement sequencing, and resource deployment. Medical Affairs starts to function as the real-time strategic intelligence function it has always aspired to be, because the data infrastructure finally supports that aspiration.
Long-Term: 2030 and Beyond
In the long view, AI in Medical Affairs becomes what email and CRM became in the previous era: invisible infrastructure. No one will talk about “AI-powered MSL tools” because the AI layer will be assumed — as unremarkable and essential as electricity. KOL intelligence will update continuously and automatically. Engagement strategies will adapt in real time based on field signals. Insights will flow from field interactions to strategic decisions without manual intervention.
The teams that adopted early will have compounding advantages. Their AI systems will have years of interaction data, refined scoring models, and accumulated institutional knowledge. Their MSLs will have spent years working in an AI-augmented mode, developing workflows and intuitions that leverage the technology naturally. Their KOL relationships will be deeper because their MSLs spent more time on scientific engagement and less time on data work. These advantages compound. They are difficult to replicate by late adopters.
This is the approach Bionara takes — building AI into the workflow layer rather than bolting it on top, so that the intelligence is embedded in every stage of the MSL workflow rather than siloed in a separate “AI feature.”
Key Takeaways
- The term “AI-powered” has lost its signal. Every pharma technology vendor claims AI capabilities. The burden is on buyers to distinguish between genuine AI architecture and a chatbot bolted onto a legacy platform.
- AI excels at the 30-40% of MSL work that is data aggregation and preparation. KOL discovery, literature monitoring, pre-call intelligence, insights synthesis, and outreach personalization are all areas where AI delivers measurable, immediate value.
- AI cannot replace the core of the MSL role. Scientific exchange, compliance judgment, relationship building, and novel scientific interpretation are irreducibly human. Any tool that promises otherwise is overselling.
- The copilot model is the correct framework. AI handles research and preparation so MSLs can focus on engagement and relationships. The result is not fewer MSLs — it is each MSL covering dramatically more ground with greater depth.
- Evaluate AI claims with five specific questions. What workflow step does it automate? Where does the data come from? How does it handle compliance? Can the MSL explain the recommendation? What happens when it is wrong?
- Early adopters will have compounding advantages. AI in Medical Affairs is not a wait-and-see technology. The organizations deploying it now are building data assets, refined models, and augmented workflows that late adopters will struggle to replicate.
The AI conversation in pharma has been dominated by extremes — breathless enthusiasm on one side, skeptical dismissal on the other. The reality, as usual, is more nuanced and more interesting. AI is not going to replace MSLs. It is not going to automate Medical Affairs. It is going to eliminate the manual data work that currently prevents MSLs from doing what they were hired to do: build scientific relationships that generate strategic intelligence. That is a significant transformation, but it is a specific one — bounded by real limitations, grounded in particular workflows, and measurable in concrete outcomes. The organizations that approach AI with this level of specificity — asking not “does it use AI?” but “what exactly does the AI do, and can I verify it?” — will be the ones that capture genuine value. The ones that chase the label will get the label and not much else. To see how other organizations have navigated this transition, explore our case studies from teams that have moved from evaluation to implementation.